AIM-listed Avacta is betting the company on clinically validating its FAP-activated pre|CISION “tumor-only” chemo platform—high upside if AVA6000/AVA6103 hit, high dilution and binary-data risk if they don’t.
Overview
Avacta Group Plc (AVCT.L) is a UK-based clinical-stage oncology biotech that has completed a major strategic overhaul to become a pure-play developer of targeted therapeutics. Its core asset is the proprietary pre|CISION platform, designed to localize the release of potent chemotherapy payloads inside tumors using a linker cleaved by Fibroblast Activation Protein (FAP)—an enzyme highly overexpressed in the stroma of most solid tumors and minimal in healthy tissue. The lead program, faridoxorubicin/AVA6000 (FAP-Dox), is a FAP-activated version of doxorubicin intended to preserve efficacy while dramatically reducing dose-limiting toxicities such as cardiotoxicity and myelosuppression. Phase 1a/1b data suggest strong tumor targeting (reported ~100-fold tumor-to-plasma ratio) and improved tolerability; in salivary gland cancer, AVA6000 has shown ~90% disease control, a notable signal in an underserved indication. In 2025 the company sold its diagnostics operations (Launch Diagnostics and Coris BioConcept), removing legacy complexity and shifting the business model from modest product revenue to milestone/partnering-driven value creation. Avacta’s near-term plan is to retain full ownership through early clinical readouts, then secure a major licensing partnership, while advancing a second clinical candidate AVA6103 (FAP-exatecan) into first-in-human dosing in Q1 2026. With cash of ~£16.9m at end-2025 and runway into Q3 2026 (helped by equity raises, asset-sale proceeds, and a restructured convertible bond), the investment hinges on upcoming clinical catalysts and the company’s ability to fund development without excessive dilution.